Nuvation Bio NUVB Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's available-for-sale debt securities - unrealized loss position (<12 months)?
- Nuvation Bio (NUVB) reported available-for-sale debt securities - unrealized loss position (<12 months) of $18.16M in Q4 2025.
- How has Nuvation Bio's available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Nuvation Bio's available-for-sale debt securities - unrealized loss position (<12 months) decreased by 86.2% year-over-year, from $131.92M to $18.16M.
- What is the long-term trend for Nuvation Bio's available-for-sale debt securities - unrealized loss position (<12 months)?
- Over 4 years (2021 to 2025), Nuvation Bio's available-for-sale debt securities - unrealized loss position (<12 months) has grown at a -56.8% compound annual growth rate (CAGR), from $523.28M to $18.16M.
- What does available-for-sale debt securities - unrealized loss position (<12 months) mean?
- This captures the fair value of available-for-sale debt securities that have been in an unrealized loss position for less than one year. It is used to evaluate short-term market fluctuations affecting the company's liquid debt holdings.